View Author
prostate cancer screening prostate cancer biopsy lead-time model patient center cohort assay study detection antigen control arm prostate volume range diverent incidence european volume risk calculator prostate cancer screening calculator table european randomized study control erspc value population number detection rate erspc risk calculator result prostate-speciwc antigen 4 ng /ml serum finland swedish cohort prostate biopsy round signiwcantly comparison prostate-speciwc rectal examination swedish netherland 4–10 finnish performance dutch cohort fi rst round 2–4 university 4–10 ng /ml probability sweden validation urology lein m 2–10 outcome dutch level ratio curve overdiagnosi belgium rotterdam speciwcity journal prediction speci interval hospital randomized european randomised study trial prostate cancer incidence analysis
3 Most Recent Publications
|
Prediction of prostate cancer in unscreened men: External validation of a risk calculator
(Article)
Vugt, H.A. van Roobol, M.J. Kranse, R. Määttänen, L. Finne, P. Hugosson, J. Bangma, C.H. Schröder, F.H. Steyerberg, E.W. |
2011-04-01
|
|
Lead-time in the european randomised study of screening for prostate cancer
(Article)
Finne, P. Fallah, M. Ciatto, S. Hugosson, J. Koning, H.J. de Moss, S. Nelen, V. Auvinen, A. |
2010-11-01
|
|
Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men
(Article)
Stephan, C. Xu, C. Wildhagen, M.F. Blijenberg, B.G. Finne, P. Stenman, U-H. Jung, K. Meyer, H.-A. Cammann, H. Graefen, M. Haese, A. Huland, H. Semjonow, A. Diamandis, E.P. Remzi, M. Djavan, B. |
2007-03-01
|
